{"id":"https://openalex.org/W2586640730","doi":"https://doi.org/10.1097/cmr.0000000000000326","title":"Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome","display_name":"Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome","alternate_titles":[],"publication_year":2017,"publication_date":"2017-02-15","ids":{"openalex":"https://openalex.org/W2586640730","doi":"https://doi.org/10.1097/cmr.0000000000000326","mag":"2586640730","pmid":"https://pubmed.ncbi.nlm.nih.gov/28146044"},"language":"en","primary_location":{"id":"doi:10.1097/cmr.0000000000000326","doi":"https://doi.org/10.1097/cmr.0000000000000326","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cmr.0000000000000326","pdf_url":null,"source":{"id":"https://openalex.org/S3207524","display_name":"Melanoma Research","issn_l":"0960-8931","issn":["0960-8931","1473-5636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2586640730"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5009934497","display_name":"Abu\u2010Sayeef Mirza","orcid":"https://orcid.org/0000-0002-1875-8966","observed_orcids":["https://orcid.org/0000-0002-1875-8966"]},"institutions":[{"id":"https://openalex.org/I2613432","display_name":"University of South Florida","ror":"https://ror.org/032db5x82","country_code":"US","type":"education","lineage":["https://openalex.org/I2613432"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sayeef Mirza","raw_affiliation_strings":["Department of Internal Medicine, University of South Florida, Tampa, Florida, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, University of South Florida, Tampa, Florida, USA","institution_ids":["https://openalex.org/I2613432"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056803233","display_name":"Ebone' Danielle Hill","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ebone\u2019 Hill","raw_affiliation_strings":["Medicine, H. Lee Moffitt Cancer Center and Research Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine, H. Lee Moffitt Cancer Center and Research Institute","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026148638","display_name":"Steven P. Ludlow","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Steven P. Ludlow","raw_affiliation_strings":["Pharmacy","fax: +1 813 745 3994","to Steven P. Ludlow, PharmD, Department of Pharmacy, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Fl 33612, USA Tel: +1 813 745 3805"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacy","institution_ids":[]},{"raw_affiliation_string":"fax: +1 813 745 3994","institution_ids":[]},{"raw_affiliation_string":"to Steven P. Ludlow, PharmD, Department of Pharmacy, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Fl 33612, USA Tel: +1 813 745 3805","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5019563078","display_name":"Sowmya Nanjappa","orcid":"https://orcid.org/0000-0002-2204-4640","observed_orcids":["https://orcid.org/0000-0002-2204-4640"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sowmya Nanjappa","raw_affiliation_strings":["Medicine, H. Lee Moffitt Cancer Center and Research Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine, H. Lee Moffitt Cancer Center and Research Institute","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5026148638"],"corresponding_institution_ids":["https://openalex.org/I3019308854"],"apc_list":null,"apc_paid":null,"fwci":2.487,"has_fulltext":false,"cited_by_count":63,"citation_normalized_percentile":{"value":0.90973337,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"27","issue":"3","first_page":"271","last_page":"273"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9818999767303467,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9818999767303467,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.013899999670684338,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/drug-reaction-with-eosinophilia-and-systemic-symptoms","display_name":"DRESS syndrome","score":0.9309999942779541},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7369999885559082},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.996999979019165},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":1.0},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8019999861717224},{"id":"https://openalex.org/keywords/immunotherapy-adverse-events","display_name":"immunotherapy adverse events","score":0.8309999704360962},{"id":"https://openalex.org/keywords/corticosteroid-therapy","display_name":"corticosteroid therapy","score":0.972000002861023},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.7089999914169312},{"id":"https://openalex.org/keywords/liver-injury","display_name":"liver injury","score":0.5550000071525574},{"id":"https://openalex.org/keywords/kidney-injury","display_name":"kidney injury","score":0.8989999890327454}],"concepts":[{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.8665398359298706},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8401443958282471},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.8108429908752441},{"id":"https://openalex.org/C2777129736","wikidata":"https://www.wikidata.org/wiki/Q505142","display_name":"Eosinophilia","level":2,"score":0.7407190799713135},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.7394577264785767},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.673811137676239},{"id":"https://openalex.org/C2780542314","wikidata":"https://www.wikidata.org/wiki/Q45959","display_name":"Adverse drug reaction","level":3,"score":0.46286118030548096},{"id":"https://openalex.org/C2993432071","wikidata":"https://www.wikidata.org/wiki/Q45959","display_name":"Drug reaction","level":3,"score":0.4374658167362213},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4289632737636566},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.3792223334312439},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3327367305755615},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.232130765914917},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.12359270453453064}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000305","descriptor_name":"Adrenal Cortex Hormones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D004802","descriptor_name":"Eosinophilia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D004802","descriptor_name":"Eosinophilia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D004802","descriptor_name":"Eosinophilia","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059447","descriptor_name":"Cell Cycle Checkpoints","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D063926","descriptor_name":"Drug Hypersensitivity Syndrome","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D063926","descriptor_name":"Drug Hypersensitivity Syndrome","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true},{"descriptor_ui":"D063926","descriptor_name":"Drug Hypersensitivity Syndrome","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/cmr.0000000000000326","doi":"https://doi.org/10.1097/cmr.0000000000000326","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cmr.0000000000000326","pdf_url":null,"source":{"id":"https://openalex.org/S3207524","display_name":"Melanoma Research","issn_l":"0960-8931","issn":["0960-8931","1473-5636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma Research","raw_type":"journal-article"},{"id":"pmid:28146044","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28146044","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma research","raw_type":"Case Reports"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W1500181468","https://openalex.org/W1529517822","https://openalex.org/W1531271463","https://openalex.org/W1605630196","https://openalex.org/W2002673340","https://openalex.org/W2063230718","https://openalex.org/W2063634266","https://openalex.org/W2073871857","https://openalex.org/W2080759679","https://openalex.org/W2084056567","https://openalex.org/W2097995306","https://openalex.org/W2106511606","https://openalex.org/W2107150019","https://openalex.org/W2107367316","https://openalex.org/W2133494322","https://openalex.org/W2140460887","https://openalex.org/W2145813455","https://openalex.org/W2151507811","https://openalex.org/W2166662937","https://openalex.org/W2177405394","https://openalex.org/W2395034671","https://openalex.org/W3037939242"],"related_works":["https://openalex.org/W4319334103","https://openalex.org/W4284711724","https://openalex.org/W2105057287","https://openalex.org/W4229448548","https://openalex.org/W4313488647","https://openalex.org/W3055131902","https://openalex.org/W2981324168","https://openalex.org/W7133141246","https://openalex.org/W4409485487","https://openalex.org/W7138945343"],"abstract_inverted_index":{"Drug":[0],"reaction":[1,13,48],"with":[2,49,67,71,85],"eosinophilia":[3,50],"and":[4,20,31,51,65],"systemic":[5,52],"symptom":[6,53],"syndrome":[7,54],"is":[8,55],"a":[9],"potentially":[10],"fatal":[11],"drug":[12,47],"that":[14,74],"must":[15],"be":[16,34],"recognized":[17],"quickly.":[18],"Ipilimumab":[19],"nivolumab":[21],"are":[22],"both":[23],"important":[24],"agents":[25],"in":[26,36,83],"the":[27,41,60,77],"treatment":[28,66],"of":[29,43,59,79],"melanoma":[30],"continue":[32],"to":[33],"studied":[35],"other":[37],"malignancies.":[38],"We":[39],"believe":[40],"mainstay":[42],"therapy":[44],"for":[45],"immunotherapy-induced":[46],"early":[56],"recognition,":[57],"discontinuation":[58],"inciting":[61],"agent,":[62],"supportive":[63],"care,":[64],"high":[68],"dose":[69],"corticosteroids":[70],"appropriate":[72],"tapers":[73],"may":[75],"reduce":[76],"length":[78],"internal":[80],"organ":[81],"injury":[82],"cases":[84],"liver":[86],"or":[87],"kidney":[88],"involvement.":[89]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2586640730","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":10},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":8},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2017-02-17T00:00:00"}
